GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations
Advanced Drug Delivery Reviews · 2026-02 · 229 · 115744
DOI: 10.1016/j.addr.2025.115744 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-02. Verfasst von Alexandra Haase und 2 weiteren Autor:innen. Beteiligte Einrichtung: Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, RE…. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Regenerative Medicine, Culture Techniques, Quality Control. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Forschung, Technologie und Raumfahrt, HORIZON EUROPE Framework Programme, European Commission.
Abstract (Originalsprache)
The development of induced pluripotent stem cells (iPSCs) has transformed the field of regenerative medicine. However, to use iPSCs for therapeutic applications, iPSC-based products must be produced under Good Manufacturing Practice (GMP) conditions. This process involves reprogramming somatic cells, characterizing and banking iPSC lines, introducing therapeutic transgenes if necessary, and scaling up cell expansion and differentiation for clinical use. This review provides an overview of the relevant regulatory authorities and relevant regulations in the US, Europe, and Japan. It also discusses the current challenges and opportunities in producing GMP-compliant iPSCs. These challenges include the need for defined culture media, as well as developing all the required GMP-compliant processes, such as reprogramming, establishing iPSC clones, and manufacturing processes that lead to the final advanced therapy medicinal product (ATMP). For autologous products in particular, this can be complicated by cell line-specific variation of proliferation velocity and differentiation biases. The review also discusses attempts to develop automated closed systems. It emphasizes the importance of ensuring the sterility, identity, (epi)genetic integrity, and functionality of the final cell products to guarantee the safety and the efficacy of iPSC-based therapies. However, the need for reproducibility, rigorous quality control and safety requirements has resulted in high regulatory hurdles and extremely high costs, which often prevent the initiation of clinical trials. Overcoming these challenges will enable iPSCs to play an integral role in future medicine and offer new treatment options for various diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, REBIRTH Cluster of Excellence, Biomedical Research in Endstage and Obstr…
Förderung
- Bundesministerium für Forschung, Technologie und Raumfahrt
- HORIZON EUROPE Framework Programme
- European Commission
- REBIRTH HANNOVER Forschungszentrum für translationale regenerative Medizin
- Deutsches Zentrum für Lungenforschung
Zitieren
APA
Haase, A., Ruhparwar, A., & Martin, U. (2026). GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations. Advanced Drug Delivery Reviews, 229, 115744. https://doi.org/10.1016/j.addr.2025.115744
Vancouver
Haase A, Ruhparwar A, Martin U. GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations. Advanced Drug Delivery Reviews. 2026;229:115744. doi:10.1016/j.addr.2025.115744
BibTeX
@article{Haase2026,
author = {Haase, Alexandra and Ruhparwar, Arjang and Martin, Ulrich},
title = {GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {229},
pages = {115744},
doi = {10.1016/j.addr.2025.115744}
}
EUVIMED